One, Two, or Three Receptors
Semaglutide, tirzepatide, and retatrutide represent three successive generations of incretin-based research compounds, distinguished by how many hormone receptors each one targets. Semaglutide activates a single receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). Retatrutide activates three (GIP, GLP-1, and glucagon). Each step in this progression has been studied as a test of whether additional receptor engagement produces additional metabolic effect.
What the Trial Data Shows
Across published randomized controlled trials, a consistent pattern emerges: each additional receptor target has been associated with a larger measured effect on body weight in trial populations.
Semaglutide's STEP trial program, evaluating the drug in people with overweight or obesity, reported weight loss ranging from approximately 6.2% to 12.4% from baseline depending on the specific trial and population studied.
Tirzepatide's SURMOUNT trial program and subsequent head-to-head comparisons have consistently shown larger reductions than semaglutide. One real-world comparative study of GLP-1-naive patients found tirzepatide users lost an average of 10.2 kg compared to 6.1 kg for semaglutide users over a comparable period, alongside larger reductions in HbA1c.
Retatrutide's Phase 2 trial, published in the New England Journal of Medicine, reported a mean weight reduction of 24.2% at 48 weeks in the highest dose group studied — the largest effect size reported for this drug class to date, in a trial where the weight-loss trajectory had not yet plateaued when treatment was stopped.
Why Adding Receptors Changes the Effect
The published research attributes tirzepatide's advantage over semaglutide to synergistic interaction between GIP and GLP-1 signaling, rather than simple additive effects of two separate pathways. Retatrutide's added glucagon receptor activity introduces a third mechanism — one that on its own increases energy expenditure, but which trial researchers note could theoretically worsen blood glucose control if not balanced by concurrent GLP-1 and GIP activity. Published trial data on retatrutide has not shown this worsening effect, suggesting the three pathways are functioning in a balanced, complementary way in the populations studied so far.
Regulatory and Development Status
Semaglutide and tirzepatide are both approved medications with established regulatory histories in multiple jurisdictions. Retatrutide, by contrast, remains an investigational compound — it has not received FDA, Health Canada, or EMA approval, and is currently in Phase 3 trials (the TRIUMPH program) rather than approved clinical use. This is a meaningful distinction: retatrutide's trial data, while striking, represents an earlier stage of the evidence-development process than the other two compounds have already completed.
Shared Safety Considerations Across the Class
All three compounds share a broadly similar side-effect profile in published trials, dominated by gastrointestinal effects (nausea, vomiting) that are typically most pronounced during dose escalation. All carry a boxed warning class effect regarding thyroid C-cell tumors, based on rodent studies, and pancreatitis risk is monitored across the drug class in ongoing trial programs.
Availability: Of the compounds compared above, Pacific Peptides stocks Tirzepatide (10mg and 30mg) and Retatrutide (20mg and 40mg). Every batch is independently third-party tested, with full certificates published on our Lab Results page.
This article is provided for general research and educational purposes. It summarizes published clinical trial literature and does not constitute guidance for human use of any compound. All products referenced are sold strictly for laboratory research use.